The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
IPE-PREVENTION is a prospective, randomized, 3-month long, open-label study. A total of 70
individuals with elevated cardio-metabolic risk and heightened triglyceride levels, and who
are on stable statin therapy will be randomized (1:1) to receive either icosapent ethyl (IPE)
2g BID or standard of care.
It is hypothesized that assignment to IPE will lower progenitor cell depletion as well as
limit progenitor cell dysfunction. This study may offer some molecular and cellular insights
into the mechanisms underlying the cardiovascular benefits of IPE therapy reported in the
REDUCE-IT trial.
Phase:
Phase 4
Details
Lead Sponsor:
Canadian Medical and Surgical Knowledge Translation Research Group
Collaborators:
HLS Therapeutics, Inc St. Michael's Hospital, Toronto Unity Health Toronto University of Western Ontario, Canada